PE Tech Report


Like this article?

Sign up to our free newsletter

Trilantic Europe acquires the Oberberg Group

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, has acquired Oberberg Group, an operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany, with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.
Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.
Henrik Bodenstab, Partner at Trilantic Europe, says: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”
Professor Michael Almeling, Speaker of the Management Board of Oberberg, says: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”
The transaction represents Trilantic Europe’s fourth investment in the healthcare sector. Closing of the transaction is expected to take place during Q4 2017.

Like this article? Sign up to our free newsletter